GSK plc (GSK) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Total Revenue Chart for GSK plc
GSK plc (GSK) revenue for FY2025 was GBP 32.7B, a 4.1% change from FY2024. GSK plc's revenue grew from GBP 1.4B in 1986 to GBP 32.7B in 2025 (2186.0% over 39 years). Earnings per share grew from GBP 0.75 in 2000 to GBP 3.66 in 2022 (386.1%). Revenue compound annual growth rate: 5-year CAGR of -0.9%, 10-year CAGR of 3.2%, 20-year CAGR of 2.1%.
Total Revenue (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £74.33B
- Implied Share Price
- £18.55
- Enterprise Value
- £93.43B
- Revenue (TTM)
- £33.54B
- EBITDA
- £11.08B
- Profit Margin
- 12.97%
- Trailing P/E
- 17.34
- Forward P/E
- 9.35
- Price/Book (MRQ)
- 3.88
- Price/Sales (TTM)
- 2.22
- EV/EBITDA
- 10.10
- EV/Revenue
- 2.79
- Dividend Yield
- 4.36%
- Book Value
- £4.68
- Free Cash Flow (FY2025)
- £5.96B
- Free Cash Flow Yield
- 8.01%
Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.